Skip to content
10-K

Annual Report

Serina Therapeutics, Inc. SER

0001708599-26-000016

← back to feed
Filed
Mar 25, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 10.19M sh
Shares Diluted FY 2025 · Dec 31, 2024 7.36M sh
Capex FY 2025 · Dec 31, 2025 $59K
Capex FY 2025 · Dec 31, 2024 $22K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$17.96M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$17.14M
Cash And Equivalents FY 2025 · Dec 31, 2025 $3.06M
Cash And Equivalents FY 2025 · Dec 31, 2024 $3.67M
Stockholders Equity FY 2025 · Dec 31, 2025 −$37K
Stockholders Equity FY 2025 · Dec 31, 2024 $641K
Current Liabilities FY 2025 · Dec 31, 2025 $3.56M
Current Liabilities FY 2025 · Dec 31, 2024 $2.37M
Total Liabilities FY 2025 · Dec 31, 2025 $6.99M
Total Liabilities FY 2025 · Dec 31, 2024 $6.22M
Current Assets FY 2025 · Dec 31, 2025 $6.08M
Current Assets FY 2025 · Dec 31, 2024 $5.68M
Total Assets FY 2025 · Dec 31, 2025 $6.95M
Total Assets FY 2025 · Dec 31, 2024 $6.72M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.91
Eps Diluted FY 2025 · Dec 31, 2024 −$1.51
Eps Basic FY 2025 · Dec 31, 2025 −$1.91
Eps Basic FY 2025 · Dec 31, 2024 −$1.51
Sga Expense FY 2025 · Dec 31, 2025 $11M
Sga Expense FY 2025 · Dec 31, 2024 $9.62M
Rd Expense FY 2025 · Dec 31, 2025 $13.16M
Rd Expense FY 2025 · Dec 31, 2024 $7.48M
Net Income FY 2025 · Dec 31, 2025 −$19.18M
Net Income FY 2025 · Dec 31, 2024 −$11.14M
Operating Income FY 2025 · Dec 31, 2025 −$24.02M
Operating Income FY 2025 · Dec 31, 2024 −$17.05M
Revenue FY 2025 · Dec 31, 2025 $130K
Revenue FY 2025 · Dec 31, 2024 $56K